Dyslipidaemia plays a key role in the development of cardiovascular disease (CVD). Therefore, identification and treatment dyslipidaemia is important for both primary secondary CVD prevention, forms basis this article.

This cross sectional study aimed to explore the association between dyslipidaemia and types of antipsychotics in 100 patients with chronic schizophrenia. Lipid profile, weight, height and waist circumference together with other relevant factors were measured. We found there was a high rate of dyslipidaemia among patients with chronic schizophrenia treated with antipsychotics (66%), however ther...

OBJECTIVES Dyslipidaemia is a major risk factor to cardiovascular disease (CVD)--the leading cause of death worldwide. Limited data are available about the prevalence of various dyslipidaemia in Canada. The objective of this study is to describe the prevalence of various single and mixed dyslipidaemia within the Canadian population in a primary care setting. SETTING A cross-sectional study, u...

Purpose of review Increased total body fat with truncal redistribution is common in antiretroviral therapy (ART)-controlled persons living HIV(PLWH), leading to insulin resistance, prediabetes/diabetes and dyslipidaemia. We address these topics here. Recent findings Most antiretrovirals are associated gain trunk fat, including visceral adipose tissue (VAT). Protease-inhibitors could inhibit whi...

BACKGROUND BMI is linearly related to the total cholesterol, LDL cholesterol and triglyceride concentrations and is, however, inversely related with HDL cholesterol, Dyslipidaemia has been recognized to be strongly associated with overweight and obesity and its comorbid conditions. Overweight and obesity is conveniently determined from body mass index (BMI). Present study was conducted in Khybe...

Background In Malaysia, cardiovascular disease is the leading cause of death. Dyslipidaemia or high cholesterol level has been identified as one of the main risk factor that causes cardiovascular disease. In line with this, a clinical practice guideline on management of dyslipidaemia has been developed in 2004 and reviewed in 2011 for the management of dyslipidaemia cases in Malaysia. Drugs inc...

Experimental studies have suggested that tea consumption could lower the risk of dyslipidaemia. However, epidemiological evidence is limited, especially in southern China, where oolong tea is the most widely consumed beverage. We conducted a population-based case-control study to evaluate the association between consumption of tea, especially oolong tea, and risk of dyslipidaemia in Shantou, so...

Given evidence of increasing prevalence in developed and developing countries, as a result of obesity trends and sedentary lifestyles, the metabolic syndrome represents an increasing burden on healthcare systems. Management guidelines for dyslipidaemia have primarily focused on LDL-C reduction; however, this approach fails to sufficiently address other lipid abnormalities associated with the me...